FDA’s ‘Access’ Challenge Highlighted At Naloxone Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
‘Behind-the-counter’ placement of opioid overdose treatment doesn’t resonate with agency, even as it wants to broaden availability.
You may also be interested in...
Naloxone Behind-the-Counter? Petition Could Help Push Action
The idea of “behind-the-counter” may be behind the times, but a request to put naloxone there could help push FDA’s existing interest in expanding access to the overdose antidote.
Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director
Nicole Verdun said children could participate in gene therapy clinical trials earlier if the necessary controls are in place.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.